Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Norway-based Affitech has acquired the full rights to the diabody technology originally owned by Pharmexa, a Danish immunotherapeutic and vaccine company.
Subscribe to our email newsletter
The acquisition follows an exclusive license of the diabody IP that Affitech obtained in 2007 from Pharmexa to carry out certain non-clinical good laboratory practice compliant studies, as well as sub-licensing arrangements with third parties, said Affitech.
Also known as bi-specific single chain antibodies, diabodies are recombinant antibody-like proteins whose unique attributes make them attractive candidates for a variety of therapeutic applications.
Martin Welschof, CEO of Affitech, said: “This is a key strategic move for Affitech, since this diabody technology complements our existing antibody discovery platform perfectly. We are delighted to have this technology under our total ownership, which will benefit both our proprietary programs and our collaborations with pharma and biotech companies. In addition we will continue to seek actively sublicensing arrangements with third parties.”